SBFM · Sunshine Biopharma, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $36.31M | $34.87M | $24.09M | $4.35M | $228.4K | $71.4K |
| Cost of Revenue | $24.05M | $24.20M | $15.75M | $2.65M | $117.8K | $25.8K |
| Gross Profit | $12.26M | $10.67M | $8.34M | $1.70M | $110.6K | $45.6K |
| R&D | $604.3K | $933.9K | $1.86M | $811.9K | $672.2K | $60.9K |
| SG&A | $18.48M | $16.48M | $13.12M | $28.70M | $2.55M | $622.4K |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $332.1K | $223.5K | $149.1K | $25.2K | $12.7K | $14.1K |
| Operating Income | ($6.23M) | ($5.81M) | ($4.79M) | ($27.00M) | ($2.44M) | ($576.9K) |
| Interest Expense | $0 | $8.8K | $137.3K | $39.4K | $328.8K | $168.1K |
| Income Tax | $21.6K | ($234.9K) | $395.2K | $233.3K | $0 | - |
| Net Income | ($5.98M) | ($5.13M) | ($4.51M) | ($26.74M) | ($12.44M) | ($2.78M) |
| EPS - Basic | ($14.40) | ($73.20) | ($3800.00) | ($35200.00) | ($95200.00) | ($200.00) |
| EPS - Diluted | - | ($73.20) | ($3800.00) | ($35200.00) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.12M | $9.69M | $16.29M | $21.83M | $2.05M | $989.9K |
| Accounts Receivable | $3.46M | $3.87M | $2.55M | $1.91M | $7.8K | $1.9K |
| Inventory | $13.47M | $11.28M | $5.73M | $3.29M | $105.7K | - |
| Accounts Payable | $5.66M | $5.54M | $2.59M | $2.80M | $42.9K | $62.9K |
| Current Assets | $26.85M | $25.97M | $24.89M | $27.31M | $2.20M | $1.03M |
| Total Assets | $30.08M | $30.56M | $27.35M | $29.24M | $2.20M | $1.05M |
| Current Liabilities | $6.44M | $6.31M | $5.55M | $6.93M | $91.2K | $1.05M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $7.04M | $7.06M | $6.14M | $7.62M | $1.99M | $2.00M |
| Stockholders' Equity | $23.04M | $23.50M | $21.21M | $21.63M | $211.7K | ($954.8K) |
| Retained Earnings | ($75.02M) | ($69.04M) | ($63.91M) | ($59.40M) | ($32.66M) | ($20.22M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.33M) | ($12.53M) | ($8.78M) | ($5.25M) | ($1.83M) | ($657.3K) |
| Investing Cash Flow | ($836.3K) | ($2.32M) | ($656.1K) | ($14.62M) | $0 | ($1.2K) |
| Financing Cash Flow | $4.75M | $9.29M | $3.43M | $39.47M | $2.90M | $1.61M |
| CapEx | $174.5K | $1.66M | $82.3K | $194.0K | $0 | $1.2K |
| Free Cash Flow | ($5.51M) | ($14.19M) | ($8.86M) | ($5.44M) | ($1.83M) | ($658.5K) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 33.8% | 30.6% | 34.6% | 39.0% | 48.4% | 63.8% |
| Operating margin | -17.2% | -16.7% | -19.9% | -621.3% | -1068.2% | -807.8% |
| EBITDA margin | -16.2% | -16.0% | -19.2% | -620.8% | -1062.7% | -788.1% |
| Net margin | -16.5% | -14.7% | -18.7% | -615.4% | -5444.4% | -3898.7% |
| Free cash flow margin | -15.2% | -40.7% | -36.8% | -125.2% | -800.8% | -922.1% |
| FCF / Net income | 0.92 | 2.76 | 1.97 | 0.20 | 0.15 | 0.24 |
| R&D / Revenue | 1.7% | 2.7% | 7.7% | 18.7% | 294.3% | 85.3% |
| SG&A / Revenue | 50.9% | 47.3% | 54.5% | 660.4% | 1116.7% | 871.6% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -19.9% | -16.8% | -16.5% | -91.5% | -564.6% | -266.3% |
| Return on equity | -25.9% | -21.8% | -21.2% | -123.7% | -5875.6% | 291.6% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.17 | 4.11 | 4.48 | 3.94 | 24.07 | 0.98 |
| Quick ratio | 2.08 | 2.33 | 3.45 | 3.47 | 22.91 | 0.98 |
| Cash ratio | 1.42 | 1.53 | 2.93 | 3.15 | 22.42 | 0.94 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -662.4x | -34.9x | -685.1x | -7.4x | -3.4x |
| Equity multiplier | 1.31 | 1.30 | 1.29 | 1.35 | 10.41 | -1.09 |
| Liabilities / Assets | 0.23 | 0.23 | 0.22 | 0.26 | 0.90 | 1.91 |
| Efficiency | ||||||
| Asset turnover | 1.21 | 1.14 | 0.88 | 0.15 | 0.10 | 0.07 |
| Inventory turnover | 1.79 | 2.15 | 2.75 | 0.81 | 1.12 | - |
| Days sales outstanding | 35d | 40d | 39d | 161d | 12d | 10d |
| Days inventory outstanding | 204d | 170d | 133d | 453d | 327d | - |
| Days payable outstanding | 86d | 84d | 60d | 386d | 133d | 888d |
| Cash conversion cycle | 153d | 127d | 112d | 228d | 207d | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | 0.1x | 6230.0x | 1545.9x | - | - |
| P / S | - | 0.1x | 5483.9x | 7693.8x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 4.1% | 44.7% | 454.4% | 1802.4% | 219.9% | 238.1% |
| Revenue CAGR (3y) | 102.9% | 434.5% | 596.2% | 490.4% | -20.1% | - |
| Revenue CAGR (5y) | 247.7% | 340.1% | 122.0% | - | - | - |
| Gross profit growth (YoY) | 14.9% | 27.9% | 391.5% | 1434.0% | 142.7% | 352.4% |
| Operating income growth (YoY) | -7.1% | -21.5% | 82.3% | -1006.5% | -323.0% | 10.1% |
| Net income growth (YoY) | -16.4% | -13.9% | 83.2% | -115.0% | -346.7% | -67.7% |
| EPS growth (YoY) | - | 98.1% | 89.2% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 61.2% | -60.2% | -62.7% | -197.5% | -177.8% | -32.6% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -2.0% | 10.8% | -1.9% | 10118.0% | - | -29.8% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.31
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Sunshine Biopharma against the 5 most active filers in the same SIC group.